Conclusions: The results emphasize that PIK3CAmut can induce immune evasion by recruiting MDSCs through the 5‐LOX‐dependent AA pathway, and combination targeted therapy with ICB may provide a promising treatment option for refractory advanced LBC patients. The gene discussed is ALOX5; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.